-
Mashup Score: 1myelocast - 7 month(s) ago
A new Flutter project.
Source: eatoure.github.ioCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0The Multiple Myeloma Daily - 1 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0IBC – Intercepting Blood Cancers - 1 year(s) ago
We are preparing a warm welcome in Madrid for the 2023 Intercepting Blood Cancers Meeting (IBC 2023). Taking place from 3-5 March 2023, the IBC 2023 Hybrid Meeting will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will…
Source: ibc2023.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study - 1 year(s) ago
iFrame is not supported! Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented i…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study - 1 year(s) ago
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study - 1 year(s) ago
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, shares some insights into the prevalence of various subtypes of monoclonal…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Shibboleth Authentication Request - 1 year(s) ago
If your browser does not continue automatically, click
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Elon Musk Outlines Roadmap for ‘Twitter 2.0’ in New Slide Deck - 1 year(s) ago
Elon’s plan for Twitter is slowly taking shape.
Source: Social Media TodayCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) - Blood Cancer Journal - 1 year(s) ago
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new risk stratification system. We included…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
RT @rexprem: If you want to estimate risk of progression in #myeloma, #SMM and #MGUS. Please visit https://t.co/gdgK0qwI2Q. Amazing work by…